Fakultni nemocnice Motol a Homolka
- Address
- V Uvalu 84/1, Motol, 150 00 Prague, Czechia
Musculoskeletal Diseases and Skin and Connective Tissue Diseases
Clinical research at Fakultni nemocnice Motol a Homolka focuses on inflammatory conditions that affect joints, skin, and connective tissues, with a strong emphasis on psoriatic arthritis. The trials are designed to assess whether new treatment options can better control disease activity and improve patient outcomes.
- Evaluating new therapies for psoriatic arthritis
- Comparing treatment effectiveness against placebo and established options
- Measuring improvement in symptoms and overall disease control
This research reflects a collaborative clinical environment in Praha, where specialists in rheumatology are working to expand treatment choices for people with active inflammatory disease.
Psoriatic Arthritis Research
The site is conducting studies centered on psoriatic arthritis, a condition that links musculoskeletal inflammation with skin and connective tissue involvement. The main goal is to determine how well emerging therapies can reduce disease signs and support better long-term management.
- Testing potential new treatment approaches for active disease
- Assessing benefit in patients who have not responded adequately to prior therapy
- Supporting better decisions in inflammatory arthritis care
With experienced investigators at Oddělení revmatologie dětí a dospělých, the research program brings together both adult and pediatric rheumatology expertise.
Inflammatory Joint and Tissue Disease Trials
These trials explore treatment strategies for diseases within the musculoskeletal and connective tissue fields, aiming to improve symptom control and overall response in people living with chronic inflammatory arthritis.
- Studying whether newer therapies can improve disease activity
- Comparing investigational treatments with reference therapies
- Advancing care for patients with persistent inflammatory joint disease
The research activity at this health care institution in Czechia highlights a strong clinical focus on practical treatment improvement rather than basic laboratory work.
Rheumatology Clinical Research
Clinical trials at the site are concentrated in rheumatology, especially conditions where inflammation affects both joints and skin. The studies aim to clarify which therapies may offer better relief for patients with active psoriatic arthritis.
- Investigating treatment effectiveness in active inflammatory disease
- Exploring options for patients with inadequate response to standard care
- Contributing to more personalized management of chronic arthritis
With a substantial investigator base, Fakultni nemocnice Motol a Homolka supports ongoing clinical evaluation of new approaches in a specialized rheumatology setting.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 25 therapeutic areas and 15 of 440 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 429 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 92 by active trials.
- 1Merck Sharp & Dohme LLC15active
lock +91 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC25trials
lock +54 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fakultni nemocnice Motol a Homolka
lock Showing 1 of 314 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | Bayer AG, Bayer Consumer Care AG | Phase I | Not Recruiting | Apr 2017 | Jun 2026 |
IMP list
lock Showing 1 of 440 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 27 | Unknown | 2015-11-06 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.